查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2093308

預測遺傳學市場－2026-2032年全球市場預測

Predictive Genetics Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，預測遺傳學市場將成長至 53.6 億美元，複合年成長率為 10.35%。

主要市場統計數據
基準年 2025 26.9億美元
預計年份：2026年 29.5億美元
預測年份 2032 53.6億美元
複合年成長率 (%) 10.35%

預測遺傳學簡介

預測遺傳學正在透過利用基因組檢測、多基因風險評估、藥物基因體學、帶因者篩檢和遺傳疾病譜分析等技術，在症狀出現之前識別遺傳風險，從而變革預防醫學。該領域融合了次世代定序、生物資訊學、臨床遺傳學、電子健康記錄和精準醫學等技術，使臨床醫生和醫療保健系統能夠從被動診斷轉向早期療育、風險分層和個人化護理計劃。基因檢測在腫瘤學、循環系統、生殖醫學、罕見疾病診斷、神經病學和藥物選擇等領域日益重要的臨床意義，進一步推動了該領域的需求。然而，其應用取決於實證臨床效用、健全的知情同意框架、完善的遺傳諮詢系統、隱私保護以及對醫療設備、檢查室和資料管治相關法規的遵守情況。隨著基因組資料集變得越來越多樣化，分析工具變得越來越複雜，預測遺傳學正在成為醫療保健提供者、公共衛生項目、保險公司、研究機構和生命科學相關人員的一項戰略能力，旨在改善預防、減少可避免的藥物不良反應並支持以患者為中心的決策。

預測遺傳學領域的變革性變化

在預測遺傳學領域，一場結構性轉變正在進行，從單基因檢測轉向整合基因組風險評估，後者結合了定序數據、家族病史、臨床記錄、生活方式因素和人群層面的證據。在臨床實踐中，基因檢測正日益融入遺傳性癌症、心血管風險、產前和孕前篩檢、罕見疾病評估以及基於藥物基因體學學的處方等診療路徑。這項轉變的促進因素包括定序成本的下降、高通量檢測設施的普及、臨床醫生對遺傳風險解讀理解的加深以及患者對預防性健康資訊日益成長的需求。然而，該領域也受到許多因素的影響，例如對直接面對消費者的基因檢測日益嚴格的審查、保險報銷的差異、獲得遺傳諮詢的機會不均以及對具有代表性的基因組參考資料集的需求。另一項重大變革是從孤立的檢測報告轉向“縱向基因組智慧”，後者允許隨著科學知識的進步對基因檢測觀察進行重新解讀。雖然這為預防性醫療保健計劃創造了機會，但也需要強大的資料管理、可互操作系統以及關於不確定性、滲透率和可控風險的透明溝通。

人工智慧對預測遺傳學的累積影響

人工智慧透過改進突變註釋、表現型匹配、多基因風險建模、文獻挖掘以及為臨床醫生提供決策支持，正在加速預測遺傳學的發展。機器學習技術可以幫助我們優先識別意義不明的突變，識別大型資料集中的基因型和表現型模式，並更有效地解讀全外EXOME和全基因組定序結果。在藥物基因體學，人工智慧驅動的分析可以將遺傳標記與藥物反應證據聯繫起來，並與臨床工作流程整合，從而支持更安全的藥物選擇。當基因組數據與電子健康記錄、影像、實驗室結果和縱向結局結合，產生更個人化的風險概況時，人工智慧的累積影響最為顯著。然而，人工智慧在預測遺傳學的臨床應用需要謹慎的檢驗、偏差監控、可解釋性和管治。從科學和倫理的角度來看，資料集的多樣性至關重要，因為基於代表性不足的人群訓練的模型可能會產生不可靠的預測，尤其是在多基因風險評分方面。因此，行業領導者優先考慮透明的演算法、經過臨床檢驗的流程、人工監督和符合監管規定的文檔，以確保人工智慧在不損害信任的前提下提高準確性。

預測遺傳學的關鍵區域見解

在亞太地區，預測遺傳學的應用主要得益於基因組醫學舉措的擴展、人們對遺傳疾病風險認知的提高，以及各大醫療系統對定序基礎設施的大量投資。擁有先進醫療技術的國家正在將基因組學融入癌症治療、罕見疾病診斷、生殖醫學和人口調查，而新興經濟體則透過公私合營進行臨床計畫和學術合作來擴大基因組學的應用範圍。歐洲的特點是監管管治、制定了國家級基因組學策略、開展了罕見疾病項目，並高度重視在嚴格的隱私框架下進行符合倫理的數據共用，支持經臨床檢驗的應用，同時對合規性提出了高要求。北美地區仍具有重要的影響力，這得益於其成熟的臨床實驗室網路、針對特定基因檢測建立的完善的保險報銷機制、精準腫瘤學的積極應用，以及基因組學在研究型醫院和專科診所的廣泛應用。該地區也積極探討病患隱私、資料所有權、保險影響以及公平取得遺傳諮詢等議題。在拉丁美洲，預測遺傳學正透過腫瘤遺傳學、產前篩檢、遺傳疾病診斷和感染疾病基因組分析基礎設施的建設逐步發展，以支持更廣泛的基因組應用，儘管都市區地區在獲取這些資源方面仍然存在差距。在非洲，基因組研究網路、新生兒和罕見疾病研究以及定序能力的提升正推動著預測遺傳學的發展，這些都有助於更廣泛地發展精準醫療，但該地區在檢測基礎設施、熟練人員的配備以及數據在全球基因組資料庫中的整合方面仍然面臨諸多限制。在中東，預測遺傳學正透過國家基因組計畫、婚前和生殖健康篩檢、遺傳疾病預防以及在遺傳疾病（特別是與近親繁殖相關的遺傳疾病）是公共衛生重點的地區投資精準醫療中心而不斷推進。

來自推動預測遺傳學引入的關鍵群體的見解

北約成員國（其中許多與發達的醫療經濟體重疊）日益關注生物安全、健康數據韌性、軍事醫學應用以及敏感基因組資訊的保護，從而強化了預測遺傳學領域網路安全和倫理監管的重要性。七國集團（G7）國家在臨床檢驗、先進定定序技術的應用、藥物基因體學研究、精準腫瘤學和衛生技術管治方面繼續發揮主導作用，但它們也面臨著成本效益證據、人才短缺和公平獲取等方面的挑戰。金磚國家擁有大規模的人口、不斷擴展的定序能力、重要的生物醫學研究議程以及對價格合理的基因檢測日益成長的需求，從而形成了一個多元化且具有影響力的基因組醫學格局。然而，成員國之間在監管成熟度、保險報銷和臨床整合方面存在顯著差異。歐盟正透過統一的資料保護標準、跨境健康資料舉措、罕見疾病參考網路以及擴大對研究和醫療服務中安全基因組資料共用的支持，引領預測遺傳學的全球發展方向。東協正崛起為預測遺傳學領域具有戰略意義的重要集團，其成員國正在加強臨床基因組學能力、數位健康基礎設施以及精準醫療領域的區域合作，儘管其在發達都市區和資源匱乏的醫療體系之間的實施情況差異很大。海灣合作理事會（GCC）正透過群體基因組學、婚前篩檢、罕見疾病識別和對精準醫療的投資，優先發展預測遺傳學，其中預防遺傳疾病和國家醫療衛生轉型計劃是主要驅動力。

主要國家預測遺傳學的發展趨勢

在中國，定序能力、精準醫療研究、生殖遺傳學、腫瘤檢測和群體基因組學正在迅速發展，但對遺傳數據的監管和跨境數據傳輸仍然是一項重大挑戰。美國擁有全球最發達的預測遺傳學環境之一，這得益於其先進的定序實驗室、精準腫瘤學計畫、藥物基因組學研究、遺傳性癌症檢測以及在各專科領域的廣泛應用，但對監管、數據隱私和保險歧視的擔憂仍然制約著其應用。日本正在推動腫瘤學、藥物基因組學、罕見疾病研究和人群健康計畫中的臨床基因組學發展，由於人口老化，人們對預防性風險評估的興趣日益濃厚。在印度，大規模的患者群體和不斷擴大的檢測能力支撐著生殖醫學、腫瘤學、心血管代謝風險和罕見疾病診斷領域對價格合理的基因檢測的需求日益成長，但遺傳諮詢和標準化仍然是重中之重。德國將強大的生物醫學研究、臨床實驗室品質標準和精準醫療的運用相結合，特別注重腫瘤學、罕見疾病和資料保護合規性。英國透過全國性的基因組醫療保健服務、罕見疾病定序、癌症基因組學以及將基因組檢測系統性地整合到公共醫療保健體系中，確立了領先地位。澳洲透過公共衛生基因組學、癌症風險計畫、新生兒篩檢的進步以及強力的研究成果的實用化，支持預測遺傳學的發展。法國正透過其國家基因組醫療保健計劃、癌症和罕見疾病計畫以及強力的公共衛生管治來推進預測遺傳學的發展。韓國正透過其先進的數位健康基礎設施、定序能力、腫瘤基因組學和國家生物數據舉措來擴展精準醫療，並將預測遺傳學定位為個人化醫療轉型的重要組成部分。義大利正透過其區域醫療保健系統和專科中心，在遺傳性癌症檢測、生殖遺傳學和罕見疾病診斷方面取得進展。加拿大正透過將基因組醫學融入公共醫療保健體系、省級精準醫療舉措、罕見疾病計畫以及強力的倫理管治來推進基因組醫學的發展，但其可及性可能因省份和臨床適應症而異。俄羅斯在醫學遺傳學、生殖篩檢和遺傳疾病診斷方面具備一定能力，但臨床實踐的可及性和國際合作條件可能因情況而異。巴西是拉丁美洲基因組醫學發展的領先中心，其在遺傳性癌症檢測、罕見疾病診斷和人群遺傳學研究方面的應用日益廣泛，但公眾可近性和區域差異仍然是重大挑戰。墨西哥正在擴大腫瘤學、生殖醫學和遺傳疾病領域的基因檢測，其需求得益於私人醫療保健的普及和不斷成長的學術專業知識。西班牙正在擴大腫瘤學、遺傳性風險評估和罕見疾病治療領域的基因組醫學應用，並得到了研究網路和公共醫療保健系統的支持。

為預測遺傳學領域的領導者提供的實用建議

產業領導者在製定預測遺傳學策略時，應優先考慮臨床效用、病患信任度和工作流程整合。各機構應投資於實證檢測方案、透明的變異解讀標準、多樣化的基因組資料集以及合格的遺傳諮詢服務，以促進負責任的應用。醫療服務提供者和實驗室應將遺傳學檢測結果整合到電子健康記錄中，並配備易於理解、可審計且符合臨床指南的決策支援功能。保險公司和醫療保健系統應基於早期診斷、提高藥物安全性、減少不必要的干預以及更有效地開展預防性護理等已證實的成果來評估預測遺傳學。資料管治必須被視為一項核心能力，包括知情同意、網路安全、匿名化、病患進入許可權以及遵守當地隱私法律。領導者還應在臨床、學術、公共衛生和技術生態系統中建立夥伴關係，以提高互通性並加速負責任的實用化。為解決公平性問題，各機構應將檢測服務範圍擴大到主要都會區以外的地區，支持人才培養，並確保基因組參考資料集包含多樣化的祖先背景，以減少風險預測中的偏差。

理解預測遺傳學的調查方法

本執行摘要基於結構化的二手研究方法，借鑒了經驗證的公共領域和行業相關資訊來源，包括監管指南、同行檢驗的科學文獻、公共衛生基因組學計畫、臨床實踐指南、衛生技術評估 (HTA) 出版物、政府舉措以及經認證的醫學遺傳學資源。此調查方法強調檢驗臨床、監管、技術和區域證據研究途徑，以識別預測遺傳學採納和實施中的一致模式。分析不涉及市場規模、市場佔有率和預測，而是專注於實證趨勢、策略促進因素、障礙、臨床應用、政策發展和區域趨勢。評估的關鍵主題包括基因組檢測方法、人工智慧 (AI) 整合、藥物基因體學、遺傳疾病篩檢、人群基因組學、保險報銷考慮、倫理框架和數據管治要求。此外，本研究方法還考慮了醫療保健基礎設施的成熟度、定序能力、遺傳諮詢的可用性、隱私法規和具有代表性的人口資料集，作為影響負責任地採用預測遺傳學的重要因素。

結論：預測遺傳學的未來

預測遺傳學正從專門的診斷工具轉變為預防醫學、個人化醫療和精準醫療的基石。其長期價值不僅取決於定序能力，還取決於臨床檢驗的解讀、數據的倫理使用、公平獲取以及與常規醫療決策的整合。人工智慧、群體基因組學、藥物基因體學和可互通的醫療記錄正在擴大遺傳風險評估的實際應用範圍，而監管機構和社會的期望也在提高透明度和課責的標準。擁有健全的臨床管治、完善的數位基礎設施、訓練有素的遺傳學專業人員和多樣化基因組資料集的地區和國家，最有能力將預測遺傳學與可衡量的健康效益聯繫起來。對於行業領導者而言，最永續的策略是將創新與實證醫學、隱私保護、患者參與和臨床應用相結合。隨著醫療保健不斷向預防和精準醫療轉型，預測遺傳學仍將是推動早期療育、更安全的治療方案和更個人化照護路徑的關鍵驅動力。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：預測遺傳學市場：依產品類型分類

  • 消耗品
  • 裝置
  • 服務
    • 遺傳諮詢
    • 定序服務
      • NGS服務
      • PCR服務
    • 檢查服務
  • 軟體

第8章：預測遺傳學市場：依測驗類型分類

  • 癌症篩檢
    • BRCA基因檢測
    • 大腸直腸癌篩檢
    • 肺癌篩檢
  • 職業篩檢
    • 擴展攜帶者篩檢
    • 單基因攜帶者
  • 藥物基因體學
    • CYP 檢測
    • 藥物代謝試驗
  • 產前檢查
    • 侵入性產前檢查
    • 非侵入性產前檢測
  • 風險評估
    • 心血管風險
    • 神經退化性疾病的風險

第9章：預測遺傳學市場：依技術分類

  • 微陣列
    • 比較基因雜合反應
    • 表現譜微陣列
  • 次世代定序
    • 標靶定序
    • 全EXOME定序
    • 全基因測序
  • 聚合酵素鏈鎖反應
    • 數位PCR
    • 即時PCR
  • 桑格定序

第10章：預測遺傳學市場：依樣本來源分類

  • 血液衍生的
  • 唾液/口腔拭子
  • 組織
  • 產前檢體

第11章：預測遺傳學市場：按應用領域分類

  • 心血管系統
    • 心臟病
    • 中風
  • 感染疾病
  • 神經病變
  • 腫瘤學
    • 乳癌
    • 結腸癌
    • 肺癌
  • 罕見疾病

第12章：預測遺傳學市場：依最終用戶分類

  • 研究和學術機構
  • 診斷檢查室
  • 醫院
  • 製藥和生物技術公司
  • 醫療服務提供方

第13章：預測遺傳學市場：按地區分類

  • 亞太地區
  • 歐洲
  • 北美洲
  • 拉丁美洲
  • 非洲
  • 中東

第14章：預測遺傳學市場：依組別分類

  • NATO
  • G7
  • BRICS
  • EU
  • ASEAN
  • GCC

第15章 預測遺傳學市場：依國家分類

  • 中國
  • 美國
  • 日本
  • 印度
  • 德國
  • 英國
  • 澳洲
  • 法國
  • 韓國
  • 義大利
  • 加拿大
  • 俄羅斯
  • 巴西
  • 墨西哥
  • 西班牙

第16章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • 23andMe Holding Co.
  • Abbott Laboratories
  • Agilent Technologies Inc.
  • Ancestry.com LLC
  • BGI Genomics Co. Ltd.
  • Bio-Rad Laboratories Inc.
  • Blueprint Medicines Corporation
  • Charles River Laboratories International Inc.
  • Color Health Inc.
  • CRISPR Therapeutics AG
  • Danaher Corporation
  • deCODE genetics ehf.
  • Editas Medicine Inc.
  • Eurofins Scientific SE
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd.
  • Foundation Medicine Inc.
  • Fulgent Genetics Inc.
  • GeneDx Holdings Corp.
  • Genscript Biotech Corporation
  • Guardant Health Inc.
  • Illumina Inc.
  • Intellia Therapeutics Inc.
  • Invitae Corporation
  • Laboratory Corporation of America Holdings
  • Myriad Genetics Inc.
  • Natera Inc.
  • Oxford Nanopore Technologies plc
  • Pacific Biosciences of California Inc.
  • Qiagen NV
  • Quest Diagnostics Incorporated
  • Thermo Fisher Scientific Inc.
Product Code: MRR-8903005C49A9

The Predictive Genetics Market is projected to grow by USD 5.36 billion at a CAGR of 10.35% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.69 billion
Estimated Year [2026] USD 2.95 billion
Forecast Year [2032] USD 5.36 billion
CAGR (%) 10.35%

Predictive Genetics Introduction

Predictive genetics is reshaping preventive healthcare by using genomic testing, polygenic risk assessment, pharmacogenomics, carrier screening, and hereditary disease profiling to identify inherited risk before symptoms emerge. The field sits at the intersection of next-generation sequencing, bioinformatics, clinical genetics, electronic health records, and precision medicine, enabling clinicians and health systems to move from reactive diagnosis toward earlier intervention, risk stratification, and personalized care planning. Demand is being reinforced by the growing clinical relevance of genetic testing in oncology, cardiology, reproductive health, rare disease diagnostics, neurology, and medication selection. At the same time, adoption depends on evidence-based clinical utility, strong consent frameworks, genetic counseling capacity, privacy protection, and compliance with evolving medical device, laboratory, and data governance regulations. As genomic datasets become more diverse and analytical tools become more sophisticated, predictive genetics is becoming a strategic capability for healthcare providers, public health programs, payers, research institutions, and life sciences stakeholders seeking to improve prevention, reduce avoidable adverse drug reactions, and support patient-centered decision-making.

Transformative Shifts in the Predictive Genetics Landscape

The predictive genetics landscape is undergoing a structural shift from single-gene testing toward integrated genomic risk assessment that combines sequencing data, family history, clinical records, lifestyle factors, and population-level evidence. In clinical practice, genetic testing is increasingly embedded into care pathways for hereditary cancers, cardiovascular risk, prenatal and preconception screening, rare disease evaluation, and pharmacogenomic prescribing. This shift is supported by lower sequencing costs, wider availability of high-throughput laboratories, growing clinician familiarity with genetic risk interpretation, and stronger patient demand for proactive health insights. However, the sector is also being shaped by rising scrutiny over direct-to-consumer genetic testing, variable reimbursement, inconsistent access to genetic counseling, and the need for representative genomic reference datasets. Another major transformation is the movement from isolated test reports to longitudinal genomic intelligence, where genetic findings can be reinterpreted as scientific evidence evolves. This creates opportunities for preventive health programs, but it also requires robust data stewardship, interoperable systems, and transparent communication around uncertainty, penetrance, and actionable risk.

Cumulative Impact of Artificial Intelligence on Predictive Genetics

Artificial intelligence is accelerating predictive genetics by improving variant annotation, phenotype matching, polygenic risk modeling, literature mining, and decision support for clinicians. Machine learning approaches can help prioritize variants of uncertain significance, identify genotype-phenotype patterns across large datasets, and support more efficient interpretation of whole-exome and whole-genome sequencing results. In pharmacogenomics, AI-enabled analytics can connect genetic markers with drug response evidence to support safer medication selection when integrated with clinical workflows. The cumulative impact of artificial intelligence is most visible where genomic data is combined with electronic health records, imaging, laboratory results, and longitudinal outcomes to generate more personalized risk profiles. However, the clinical use of AI in predictive genetics requires careful validation, bias monitoring, explainability, and governance. Models trained on underrepresented populations can produce less reliable predictions, particularly in polygenic risk scoring, making dataset diversity a central scientific and ethical requirement. Industry leaders are therefore prioritizing transparent algorithms, clinically validated pipelines, human oversight, and regulatory-ready documentation to ensure that AI improves accuracy without weakening trust.

Key Regional Insights Across Predictive Genetics

In Asia-Pacific, predictive genetics adoption is being propelled by expanding genomic medicine initiatives, rising awareness of hereditary disease risk, and significant investment in sequencing infrastructure across major healthcare systems. Countries with advanced medical technology capacity are integrating genomics into cancer care, rare disease diagnosis, reproductive health, and population research, while emerging economies are expanding access through public-private clinical programs and academic collaborations. Europe is characterized by strong regulatory governance, national genomics strategies, rare disease programs, and emphasis on ethical data sharing under strict privacy frameworks, supporting clinically validated use while placing high demands on compliance. North America remains a highly influential region due to mature clinical laboratory networks, established reimbursement pathways for selected genetic tests, strong use of precision oncology, and extensive integration of genomics into research hospitals and specialty care. The region also faces active debate over patient privacy, data ownership, insurance implications, and equitable access to genetic counseling. Latin America is seeing gradual growth in predictive genetics through oncology genetics, prenatal screening, inherited disease diagnostics, and infectious disease genomics infrastructure adapted for broader genomic applications, although access remains uneven across urban and rural populations. Africa is building momentum through genomic research networks, newborn and rare disease initiatives, and sequencing capacity that can support broader precision health development, but the region continues to face constraints related to laboratory infrastructure, specialist workforce availability, and representation in global genomic databases. The Middle East is advancing predictive genetics through national genome programs, premarital and reproductive screening, hereditary disease prevention, and investment in precision medicine centers, particularly where consanguinity-related inherited conditions are a public health priority.

Key Group Insights Shaping Predictive Genetics Adoption

NATO member countries, many of which overlap with advanced healthcare economies, are increasingly attentive to biosecurity, health data resilience, military medicine applications, and protection of sensitive genomic information, reinforcing the importance of cybersecurity and ethical oversight in predictive genetics. G7 economies continue to lead in clinical validation, advanced sequencing adoption, pharmacogenomics research, precision oncology, and health technology governance, while also confronting challenges linked to cost-effectiveness evidence, workforce shortages, and equitable access. BRICS countries represent a diverse and influential genomic medicine environment, combining large populations, expanding sequencing capabilities, major biomedical research agendas, and rising demand for affordable genetic testing; however, regulatory maturity, reimbursement, and clinical integration differ significantly across members. The European Union is shaping the global direction of predictive genetics through harmonized data protection standards, cross-border health data initiatives, rare disease reference networks, and growing support for secure genomic data sharing in research and care delivery. ASEAN is emerging as a strategically important group for predictive genetics as member states strengthen clinical genomics capacity, digital health infrastructure, and regional collaboration in precision medicine, though adoption varies widely between advanced urban centers and resource-constrained health systems. The GCC is prioritizing predictive genetics through population genomics, premarital screening, rare disease identification, and precision healthcare investments, with hereditary disorder prevention and national health transformation programs serving as major drivers.

Key Country Insights in Predictive Genetics

China has rapidly scaled sequencing capacity, precision medicine research, reproductive genetics, oncology testing, and population genomics, while regulatory oversight of genetic data and cross-border data transfer remains central. The United States has one of the most developed predictive genetics environments, supported by advanced sequencing laboratories, precision oncology programs, pharmacogenomic research, hereditary cancer testing, and widespread specialty adoption, while regulatory scrutiny, data privacy, and insurance discrimination concerns continue to shape implementation. Japan has advanced clinical genomics in oncology, pharmacogenomics, rare disease research, and population health programs, with an aging population strengthening interest in preventive risk assessment. India is experiencing rising demand for affordable genetic testing in reproductive health, oncology, cardiometabolic risk, and rare disease diagnosis, supported by a large patient base and expanding laboratory capacity, but genetic counseling and standardization remain priorities. Germany combines strong biomedical research, clinical laboratory quality standards, and precision medicine adoption, with particular emphasis on oncology, rare diseases, and data protection compliance. The United Kingdom has established a prominent position through national genomic medicine services, rare disease sequencing, cancer genomics, and structured integration of genomic testing into public healthcare pathways. Australia supports predictive genetics through public health genomics, cancer risk programs, newborn screening evolution, and strong research translation. France is advancing predictive genetics through national genomic medicine planning, cancer and rare disease programs, and strong public health governance. South Korea is expanding precision medicine through advanced digital health infrastructure, sequencing capability, oncology genomics, and national bio-data initiatives, positioning predictive genetics as part of broader personalized healthcare transformation. Italy is progressing in hereditary cancer testing, reproductive genetics, and rare disease diagnosis through regional healthcare systems and specialized centers. Canada is advancing genomics through public healthcare integration, provincial precision medicine initiatives, rare disease programs, and strong ethical governance, though access can vary by province and clinical indication. Russia has capabilities in medical genetics, reproductive screening, and inherited disease diagnostics, although clinical access and international collaboration conditions can vary. Brazil is the leading Latin American center for genomic medicine development, with increasing use of hereditary cancer testing, rare disease diagnostics, and population genetics research, while public access and regional disparities remain key issues. Mexico is expanding genetic testing in oncology, reproductive medicine, and inherited disorders, with demand supported by private healthcare access and growing academic expertise. Spain has expanded genomic medicine in oncology, familial risk assessment, and rare disease care, supported by research networks and public healthcare delivery.

Actionable Recommendations for Predictive Genetics Leaders

Industry leaders should prioritize clinical utility, patient trust, and workflow integration when developing predictive genetics strategies. Organizations should invest in evidence-based testing panels, transparent variant interpretation standards, diverse genomic datasets, and access to qualified genetic counseling to improve responsible adoption. Healthcare providers and laboratories should embed genetic insights into electronic health records with decision support that is understandable, auditable, and aligned with clinical guidelines. Payers and health systems should evaluate predictive genetics based on demonstrated outcomes such as earlier diagnosis, improved medication safety, reduced unnecessary procedures, and better preventive care targeting. Data governance must be treated as a core capability, including informed consent, cybersecurity, de-identification, patient access rights, and compliance with regional privacy laws. Leaders should also build partnerships across clinical, academic, public health, and technology ecosystems to improve interoperability and accelerate responsible translation. To address equity, organizations should expand testing access beyond major urban centers, support workforce training, and ensure genomic reference datasets include diverse ancestries to reduce bias in risk prediction.

Research Methodology for Predictive Genetics Insights

This executive summary is developed using a structured secondary research approach grounded in verified public-domain and industry-relevant sources, including regulatory guidance, peer-reviewed scientific literature, public health genomics programs, clinical practice guidelines, health technology assessment publications, government genome initiatives, and recognized medical genetics resources. The methodology emphasizes triangulation across clinical, regulatory, technological, and regional evidence to identify consistent patterns in predictive genetics adoption and implementation. The analysis excludes market sizing, market share, and forecasting, focusing instead on evidence-backed trends, strategic drivers, barriers, clinical applications, policy developments, and regional dynamics. Key themes were assessed across genomic testing modalities, artificial intelligence integration, pharmacogenomics, hereditary disease screening, population genomics, reimbursement considerations, ethical frameworks, and data governance requirements. The research approach also considers the maturity of healthcare infrastructure, sequencing capacity, genetic counseling availability, privacy regulation, and representative population datasets as critical factors influencing the responsible deployment of predictive genetics.

Conclusion: The Future of Predictive Genetics

Predictive genetics is moving from a specialized diagnostic tool into a foundational pillar of preventive, personalized, and precision healthcare. Its long-term value depends not only on sequencing capability, but also on clinically validated interpretation, ethical use of data, equitable access, and integration into everyday care decisions. Artificial intelligence, population genomics, pharmacogenomics, and interoperable health records are expanding the practical impact of genetic risk assessment, while regulatory and societal expectations are raising the bar for transparency and accountability. Regions and countries with strong clinical governance, robust digital infrastructure, trained genetics professionals, and diverse genomic datasets are best positioned to translate predictive genetics into measurable health benefits. For industry leaders, the most sustainable strategy is to align innovation with evidence, privacy, patient engagement, and clinical actionability. As healthcare continues to shift toward prevention and precision medicine, predictive genetics will remain a critical enabler of earlier intervention, safer treatment selection, and more personalized care pathways.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Predictive Genetics Market, by Product Type

  • 7.1. Introduction
  • 7.2. Consumables
  • 7.3. Instruments
  • 7.4. Services
    • 7.4.1. Genetic Counseling
    • 7.4.2. Sequencing Service
      • 7.4.2.1. NGS Service
      • 7.4.2.2. PCR Service
    • 7.4.3. Testing Service
  • 7.5. Software

8. Predictive Genetics Market, by Test Type

  • 8.1. Introduction
  • 8.2. Cancer Screening
    • 8.2.1. BRCA Testing
    • 8.2.2. Colorectal Cancer Screening
    • 8.2.3. Lung Cancer Screening
  • 8.3. Carrier Screening
    • 8.3.1. Expanded Carrier
    • 8.3.2. Single Gene Carrier
  • 8.4. Pharmacogenomics
    • 8.4.1. CYP Testing
    • 8.4.2. Drug Metabolism Testing
  • 8.5. Prenatal Testing
    • 8.5.1. Invasive Prenatal Testing
    • 8.5.2. Non Invasive Prenatal Testing
  • 8.6. Risk Assessment
    • 8.6.1. Cardiovascular Risk
    • 8.6.2. Neurodegenerative Risk

9. Predictive Genetics Market, by Technology

  • 9.1. Introduction
  • 9.2. Microarray
    • 9.2.1. Comparative Genomic Hybridization
    • 9.2.2. Expression Microarray
  • 9.3. Next Generation Sequencing
    • 9.3.1. Targeted Sequencing
    • 9.3.2. Whole Exome Sequencing
    • 9.3.3. Whole Genome Sequencing
  • 9.4. Polymerase Chain Reaction
    • 9.4.1. Digital PCR
    • 9.4.2. Real Time PCR
  • 9.5. Sanger Sequencing

10. Predictive Genetics Market, by Sample Source

  • 10.1. Introduction
  • 10.2. Blood-based
  • 10.3. Saliva/Oral Swab
  • 10.4. Tissue
  • 10.5. Prenatal Samples

11. Predictive Genetics Market, by Application

  • 11.1. Introduction
  • 11.2. Cardiovascular
    • 11.2.1. Heart Disease
    • 11.2.2. Stroke
  • 11.3. Infectious Diseases
  • 11.4. Neurological Disorders
  • 11.5. Oncology
    • 11.5.1. Breast Cancer
    • 11.5.2. Colorectal Cancer
    • 11.5.3. Lung Cancer
  • 11.6. Rare Diseases

12. Predictive Genetics Market, by End User

  • 12.1. Introduction
  • 12.2. Research & Academic Institutions
  • 12.3. Diagnostic Laboratories
  • 12.4. Hospitals
  • 12.5. Pharmaceutical & Biotech Companies
  • 12.6. Healthcare Providers

13. Predictive Genetics Market, by Region

  • 13.1. Asia-Pacific
  • 13.2. Europe
  • 13.3. North America
  • 13.4. Latin America
  • 13.5. Africa
  • 13.6. Middle East

14. Predictive Genetics Market, by Group

  • 14.1. NATO
  • 14.2. G7
  • 14.3. BRICS
  • 14.4. European Union
  • 14.5. ASEAN
  • 14.6. GCC

15. Predictive Genetics Market, by Country

  • 15.1. China
  • 15.2. United States
  • 15.3. Japan
  • 15.4. India
  • 15.5. Germany
  • 15.6. United Kingdom
  • 15.7. Australia
  • 15.8. France
  • 15.9. South Korea
  • 15.10. Italy
  • 15.11. Canada
  • 15.12. Russia
  • 15.13. Brazil
  • 15.14. Mexico
  • 15.15. Spain

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2025
  • 16.2. FPNV Positioning Matrix, 2025
  • 16.3. Market Concentration Analysis, 2025
    • 16.3.1. Concentration Ratio (CR)
    • 16.3.2. Herfindahl Hirschman Index (HHI)
  • 16.4. Recent Developments & Impact Analysis, 2025
  • 16.5. Product Portfolio Analysis, 2025
  • 16.6. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. 23andMe Holding Co.
  • 17.2. Abbott Laboratories
  • 17.3. Agilent Technologies Inc.
  • 17.4. Ancestry.com LLC
  • 17.5. BGI Genomics Co. Ltd.
  • 17.6. Bio-Rad Laboratories Inc.
  • 17.7. Blueprint Medicines Corporation
  • 17.8. Charles River Laboratories International Inc.
  • 17.9. Color Health Inc.
  • 17.10. CRISPR Therapeutics AG
  • 17.11. Danaher Corporation
  • 17.12. deCODE genetics ehf.
  • 17.13. Editas Medicine Inc.
  • 17.14. Eurofins Scientific SE
  • 17.15. Exact Sciences Corporation
  • 17.16. F. Hoffmann-La Roche Ltd.
  • 17.17. Foundation Medicine Inc.
  • 17.18. Fulgent Genetics Inc.
  • 17.19. GeneDx Holdings Corp.
  • 17.20. Genscript Biotech Corporation
  • 17.21. Guardant Health Inc.
  • 17.22. Illumina Inc.
  • 17.23. Intellia Therapeutics Inc.
  • 17.24. Invitae Corporation
  • 17.25. Laboratory Corporation of America Holdings
  • 17.26. Myriad Genetics Inc.
  • 17.27. Natera Inc.
  • 17.28. Oxford Nanopore Technologies plc
  • 17.29. Pacific Biosciences of California Inc.
  • 17.30. Qiagen N.V.
  • 17.31. Quest Diagnostics Incorporated
  • 17.32. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PREDICTIVE GENETICS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL PREDICTIVE GENETICS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL PREDICTIVE GENETICS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL PREDICTIVE GENETICS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL PREDICTIVE GENETICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY TEST TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY SAMPLE SOURCE, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY SAMPLE SOURCE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL PREDICTIVE GENETICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 25. GLOBAL PREDICTIVE GENETICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL PREDICTIVE GENETICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL PREDICTIVE GENETICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CONSUMABLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CONSUMABLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CONSUMABLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL INSTRUMENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL INSTRUMENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL INSTRUMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL GENETIC COUNSELING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL GENETIC COUNSELING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL GENETIC COUNSELING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL SEQUENCING SERVICE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL SEQUENCING SERVICE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL SEQUENCING SERVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL NGS SERVICE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL NGS SERVICE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL NGS SERVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PCR SERVICE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PCR SERVICE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PCR SERVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL TESTING SERVICE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL TESTING SERVICE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL TESTING SERVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL SOFTWARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL SOFTWARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL SOFTWARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CANCER SCREENING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CANCER SCREENING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BRCA TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BRCA TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BRCA TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL COLORECTAL CANCER SCREENING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL COLORECTAL CANCER SCREENING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL COLORECTAL CANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL LUNG CANCER SCREENING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL LUNG CANCER SCREENING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL LUNG CANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CARRIER SCREENING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CARRIER SCREENING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CARRIER SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL EXPANDED CARRIER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL EXPANDED CARRIER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL EXPANDED CARRIER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL SINGLE GENE CARRIER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL SINGLE GENE CARRIER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL SINGLE GENE CARRIER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL PHARMACOGENOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CYP TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CYP TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CYP TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL DRUG METABOLISM TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL DRUG METABOLISM TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL DRUG METABOLISM TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL PRENATAL TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL PRENATAL TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL PRENATAL TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL INVASIVE PRENATAL TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL INVASIVE PRENATAL TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL INVASIVE PRENATAL TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL NON INVASIVE PRENATAL TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL NON INVASIVE PRENATAL TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL NON INVASIVE PRENATAL TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL RISK ASSESSMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL RISK ASSESSMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL RISK ASSESSMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CARDIOVASCULAR RISK MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CARDIOVASCULAR RISK MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CARDIOVASCULAR RISK MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL NEURODEGENERATIVE RISK MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL NEURODEGENERATIVE RISK MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL NEURODEGENERATIVE RISK MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL MICROARRAY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL MICROARRAY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL MICROARRAY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL COMPARATIVE GENOMIC HYBRIDIZATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL COMPARATIVE GENOMIC HYBRIDIZATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL COMPARATIVE GENOMIC HYBRIDIZATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL EXPRESSION MICROARRAY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL EXPRESSION MICROARRAY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL EXPRESSION MICROARRAY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL WHOLE EXOME SEQUENCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL WHOLE EXOME SEQUENCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL WHOLE EXOME SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL WHOLE GENOME SEQUENCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL WHOLE GENOME SEQUENCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL WHOLE GENOME SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL POLYMERASE CHAIN REACTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL POLYMERASE CHAIN REACTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL POLYMERASE CHAIN REACTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL DIGITAL PCR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL DIGITAL PCR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL DIGITAL PCR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL REAL TIME PCR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL REAL TIME PCR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL REAL TIME PCR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL SANGER SEQUENCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL SANGER SEQUENCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL SANGER SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY SAMPLE SOURCE, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL BLOOD-BASED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL BLOOD-BASED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL BLOOD-BASED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL SALIVA/ORAL SWAB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL SALIVA/ORAL SWAB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL SALIVA/ORAL SWAB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL TISSUE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL TISSUE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL TISSUE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL PRENATAL SAMPLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL PRENATAL SAMPLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL PRENATAL SAMPLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL CARDIOVASCULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL CARDIOVASCULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL CARDIOVASCULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL HEART DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL HEART DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL HEART DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL STROKE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL STROKE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL STROKE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL NEUROLOGICAL DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL NEUROLOGICAL DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL NEUROLOGICAL DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL ONCOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL ONCOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL BREAST CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL BREAST CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL BREAST CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL COLORECTAL CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL COLORECTAL CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL COLORECTAL CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL LUNG CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL LUNG CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL RARE DISEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL RARE DISEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL RARE DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL RESEARCH & ACADEMIC INSTITUTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL RESEARCH & ACADEMIC INSTITUTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL RESEARCH & ACADEMIC INSTITUTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL PHARMACEUTICAL & BIOTECH COMPANIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL PHARMACEUTICAL & BIOTECH COMPANIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL PHARMACEUTICAL & BIOTECH COMPANIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL HEALTHCARE PROVIDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL HEALTHCARE PROVIDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL HEALTHCARE PROVIDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC PREDICTIVE GENETICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC PREDICTIVE GENETICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC PREDICTIVE GENETICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC PREDICTIVE GENETICS MARKET SIZE, BY SEQUENCING SERVICE, 2018-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC PREDICTIVE GENETICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC PREDICTIVE GENETICS MARKET SIZE, BY CANCER SCREENING, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC PREDICTIVE GENETICS MARKET SIZE, BY CARRIER SCREENING, 2018-2032 (USD MILLION)
  • TABLE 182. ASIA-PACIFIC PREDICTIVE GENETICS MARKET SIZE, BY PHARMACOGENOMICS, 2018-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC PREDICTIVE GENETICS MARKET SIZE, BY PRENATAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC PREDICTIVE GENETICS MARKET SIZE, BY RISK ASSESSMENT, 2018-2032 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC PREDICTIVE GENETICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC PREDICTIVE GENETICS MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC PREDICTIVE GENETICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 188. ASIA-PACIFIC PREDICTIVE GENETICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC PREDICTIVE GENETICS MARKET SIZE, BY SAMPLE SOURCE, 2018-2032 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC PREDICTIVE GENETICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 191. ASIA-PACIFIC PREDICTIVE GENETICS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 192. ASIA-PACIFIC PREDICTIVE GENETICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC PREDICTIVE GENETICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE PREDICTIVE GENETICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE PREDICTIVE GENETICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE PREDICTIVE GENETICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE PREDICTIVE GENETICS MARKET SIZE, BY SEQUENCING SERVICE, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE PREDICTIVE GENETICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE PREDICTIVE GENETICS MARKET SIZE, BY CANCER SCREENING, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE PREDICTIVE GENETICS MARKET SIZE, BY CARRIER SCREENING, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE PREDICTIVE GENETICS MARKET SIZE, BY PHARMACOGENOMICS, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE PREDICTIVE GENETICS MARKET SIZE, BY PRENATAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPE PREDICTIVE GENETICS MARKET SIZE, BY RISK ASSESSMENT, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPE PREDICTIVE GENETICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE PREDICTIVE GENETICS MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPE PREDICTIVE GENETICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPE PREDICTIVE GENETICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPE PREDICTIVE GENETICS MARKET SIZE, BY SAMPLE SOURCE, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPE PREDICTIVE GENETICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPE PREDICTIVE GENETICS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPE PREDICTIVE GENETICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPE PREDICTIVE GENETICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA PREDICTIVE GENETICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 214. NORTH AMERICA PREDICTIVE GENETICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. NORTH AMERICA PREDICTIVE GENETICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 216. NORTH AMERICA PREDICTIVE GENETICS MARKET SIZE, BY SEQUENCING SERVICE, 2018-2032 (USD MILLION)
  • TABLE 217. NORTH AMERICA PREDICTIVE GENETICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. NORTH AMERICA PREDICTIVE GENETICS MARKET SIZE, BY CANCER SCREENING, 2018-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA PREDICTIVE GENETICS MARKET SIZE, BY CARRIER SCREENING, 2018-2032 (USD MILLION)
  • TABLE 220. NORTH AMERICA PREDICTIVE GENETICS MARKET SIZE, BY PHARMACOGENOMICS, 2018-2032 (USD MILLION)
  • TABLE 221. NORTH AMERICA PREDICTIVE GENETICS MARKET SIZE, BY PRENATAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 222. NORTH AMERICA PREDICTIVE GENETICS MARKET SIZE, BY RISK ASSESSMENT, 2018-2032 (USD MILLION)
  • TABLE 223. NORTH AMERICA PREDICTIVE GENETICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 224. NORTH AMERICA PREDICTIVE GENETICS MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA PREDICTIVE GENETICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 226. NORTH AMERICA PREDICTIVE GENETICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 227. NORTH AMERICA PREDICTIVE GENETICS MARKET SIZE, BY SAMPLE SOURCE, 2018-2032 (USD MILLION)
  • TABLE 228. NORTH AMERICA PREDICTIVE GENETICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 229. NORTH AMERICA PREDICTIVE GENETICS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 230. NORTH AMERICA PREDICTIVE GENETICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA PREDICTIVE GENETICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 232. LATIN AMERICA PREDICTIVE GENETICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 233. LATIN AMERICA PREDICTIVE GENETICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. LATIN AMERICA PREDICTIVE GENETICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 235. LATIN AMERICA PREDICTIVE GENETICS MARKET SIZE, BY SEQUENCING SERVICE, 2018-2032 (USD MILLION)
  • TABLE 236. LATIN AMERICA PREDICTIVE GENETICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 237. LATIN AMERICA PREDICTIVE GENETICS MARKET SIZE, BY CANCER SCREENING, 2018-2032 (USD MILLION)
  • TABLE 238. LATIN AMERICA PREDICTIVE GENETICS MARKET SIZE, BY CARRIER SCREENING, 2018-2032 (USD MILLION)
  • TABLE 239. LATIN AMERICA PREDICTIVE GENETICS MARKET SIZE, BY PHARMACOGENOMICS, 2018-2032 (USD MILLION)
  • TABLE 240. LATIN AMERICA PREDICTIVE GENETICS MARKET SIZE, BY PRENATAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 241. LATIN AMERICA PREDICTIVE GENETICS MARKET SIZE, BY RISK ASSESSMENT, 2018-2032 (USD MILLION)
  • TABLE 242. LATIN AMERICA PREDICTIVE GENETICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 243. LATIN AMERICA PREDICTIVE GENETICS MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 244. LATIN AMERICA PREDICTIVE GENETICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 245. LATIN AMERICA PREDICTIVE GENETICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 246. LATIN AMERICA PREDICTIVE GENETICS MARKET SIZE, BY SAMPLE SOURCE, 2018-2032 (USD MILLION)
  • TABLE 247. LATIN AMERICA PREDICTIVE GENETICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 248. LATIN AMERICA PREDICTIVE GENETICS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 249. LATIN AMERICA PREDICTIVE GENETICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 250. LATIN AMERICA PREDICTIVE GENETICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 251. AFRICA PREDICTIVE GENETICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 252. AFRICA PREDICTIVE GENETICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 253. AFRICA PREDICTIVE GENETICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 254. AFRICA PREDICTIVE GENETICS MARKET SIZE, BY SEQUENCING SERVICE, 2018-2032 (USD MILLION)
  • TABLE 255. AFRICA PREDICTIVE GENETICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 256. AFRICA PREDICTIVE GENETICS MARKET SIZE, BY CANCER SCREENING, 2018-2032 (USD MILLION)
  • TABLE 257. AFRICA PREDICTIVE GENETICS MARKET SIZE, BY CARRIER SCREENING, 2018-2032 (USD MILLION)
  • TABLE 258. AFRICA PREDICTIVE GENETICS MARKET SIZE, BY PHARMACOGENOMICS, 2018-2032 (USD MILLION)
  • TABLE 259. AFRICA PREDICTIVE GENETICS MARKET SIZE, BY PRENATAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 260. AFRICA PREDICTIVE GENETICS MARKET SIZE, BY RISK ASSESSMENT, 2018-2032 (USD MILLION)
  • TABLE 261. AFRICA PREDICTIVE GENETICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 262. AFRICA PREDICTIVE GENETICS MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 263. AFRICA PREDICTIVE GENETICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 264. AFRICA PREDICTIVE GENETICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 265. AFRICA PREDICTIVE GENETICS MARKET SIZE, BY SAMPLE SOURCE, 2018-2032 (USD MILLION)
  • TABLE 266. AFRICA PREDICTIVE GENETICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 267. AFRICA PREDICTIVE GENETICS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 268. AFRICA PREDICTIVE GENETICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 269. AFRICA PREDICTIVE GENETICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 270. MIDDLE EAST PREDICTIVE GENETICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 271. MIDDLE EAST PREDICTIVE GENETICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 272. MIDDLE EAST PREDICTIVE GENETICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 273. MIDDLE EAST PREDICTIVE GENETICS MARKET SIZE, BY SEQUENCING SERVICE, 2018-2032 (USD MILLION)
  • TABLE 274. MIDDLE EAST PREDICTIVE GENETICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 275. MIDDLE EAST PREDICTIVE GENETICS MARKET SIZE, BY CANCER SCREENING, 2018-2032 (USD MILLION)
  • TABLE 276. MIDDLE EAST PREDICTIVE GENETICS MARKET SIZE, BY CARRIER SCREENING, 2018-2032 (USD MILLION)
  • TABLE 277. MIDDLE EAST PREDICTIVE GENETICS MARKET SIZE, BY PHARMACOGENOMICS, 2018-2032 (USD MILLION)
  • TABLE 278. MIDDLE EAST PREDICTIVE GENETICS MARKET SIZE, BY PRENATAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 279. MIDDLE EAST PREDICTIVE GENETICS MARKET SIZE, BY RISK ASSESSMENT, 2018-2032 (USD MILLION)
  • TABLE 280. MIDDLE EAST PREDICTIVE GENETICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 281. MIDDLE EAST PREDICTIVE GENETICS MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 282. MIDDLE EAST PREDICTIVE GENETICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 283. MIDDLE EAST PREDICTIVE GENETICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 284. MIDDLE EAST PREDICTIVE GENETICS MARKET SIZE, BY SAMPLE SOURCE, 2018-2032 (USD MILLION)
  • TABLE 285. MIDDLE EAST PREDICTIVE GENETICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 286. MIDDLE EAST PREDICTIVE GENETICS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 287. MIDDLE EAST PREDICTIVE GENETICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 288. MIDDLE EAST PREDICTIVE GENETICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 289. GLOBAL PREDICTIVE GENETICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 290. NATO PREDICTIVE GENETICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 291. NATO PREDICTIVE GENETICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 292. NATO PREDICTIVE GENETICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 293. NATO PREDICTIVE GENETICS MARKET SIZE, BY SEQUENCING SERVICE, 2018-2032 (USD MILLION)
  • TABLE 294. NATO PREDICTIVE GENETICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 295. NATO PREDICTIVE GENETICS MARKET SIZE, BY CANCER SCREENING, 2018-2032 (USD MILLION)
  • TABLE 296. NATO PREDICTIVE GENETICS MARKET SIZE, BY CARRIER SCREENING, 2018-2032 (USD MILLION)
  • TABLE 297. NATO PREDICTIVE GENETICS MARKET SIZE, BY PHARMACOGENOMICS, 2018-2032 (USD MILLION)
  • TABLE 298. NATO PREDICTIVE GENETICS MARKET SIZE, BY PRENATAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 299. NATO PREDICTIVE GENETICS MARKET SIZE, BY RISK ASSESSMENT, 2018-2032 (USD MILLION)
  • TABLE 300. NATO PREDICTIVE GENETICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 301. NATO PREDICTIVE GENETICS MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 302. NATO PREDICTIVE GENETICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 303. NATO PREDICTIVE GENETICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 304. NATO PREDICTIVE GENETICS MARKET SIZE, BY SAMPLE SOURCE, 2018-2032 (USD MILLION)
  • TABLE 305. NATO PREDICTIVE GENETICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 306. NATO PREDICTIVE GENETICS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 307. NATO PREDICTIVE GENETICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 308. NATO PREDICTIVE GENETICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 309. G7 PREDICTIVE GENETICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 310. G7 PREDICTIVE GENETICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 311. G7 PREDICTIVE GENETICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 312. G7 PREDICTIVE GENETICS MARKET SIZE, BY SEQUENCING SERVICE, 2018-2032 (USD MILLION)
  • TABLE 313. G7 PREDICTIVE GENETICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 314. G7 PREDICTIVE GENETICS MARKET SIZE, BY CANCER SCREENING, 2018-2032 (USD MILLION)
  • TABLE 315. G7 PREDICTIVE GENETICS MARKET SIZE, BY CARRIER SCREENING, 2018-2032 (USD MILLION)
  • TABLE 316. G7 PREDICTIVE GENETICS MARKET SIZE, BY PHARMACOGENOMICS, 2018-2032 (USD MILLION)
  • TABLE 317. G7 PREDICTIVE GENETICS MARKET SIZE, BY PRENATAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 318. G7 PREDICTIVE GENETICS MARKET SIZE, BY RISK ASSESSMENT, 2018-2032 (USD MILLION)
  • TABLE 319. G7 PREDICTIVE GENETICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 320. G7 PREDICTIVE GENETICS MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 321. G7 PREDICTIVE GENETICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 322. G7 PREDICTIVE GENETICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 323. G7 PREDICTIVE GENETICS MARKET SIZE, BY SAMPLE SOURCE, 2018-2032 (USD MILLION)
  • TABLE 324. G7 PREDICTIVE GENETICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 325. G7 PREDICTIVE GENETICS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 326. G7 PREDICTIVE GENETICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 327. G7 PREDICTIVE GENETICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 328. BRICS PREDICTIVE GENETICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 329. BRICS PREDICTIVE GENETICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 330. BRICS PREDICTIVE GENETICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 331. BRICS PREDICTIVE GENETICS MARKET SIZE, BY SEQUENCING SERVICE, 2018-2032 (USD MILLION)
  • TABLE 332. BRICS PREDICTIVE GENETICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 333. BRICS PREDICTIVE GENETICS MARKET SIZE, BY CANCER SCREENING, 2018-2032 (USD MILLION)
  • TABLE 334. BRICS PREDICTIVE GENETICS MARKET SIZE, BY CARRIER SCREENING, 2018-2032 (USD MILLION)
  • TABLE 335. BRICS PREDICTIVE GENETICS MARKET SIZE, BY PHARMACOGENOMICS, 2018-2032 (USD MILLION)
  • TABLE 336. BRICS PREDICTIVE GENETICS MARKET SIZE, BY PRENATAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 337. BRICS PREDICTIVE GENETICS MARKET SIZE, BY RISK ASSESSMENT, 2018-2032 (USD MILLION)
  • TABLE 338. BRICS PREDICTIVE GENETICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 339. BRICS PREDICTIVE GENETICS MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 340. BRICS PREDICTIVE GENETICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 341. BRICS PREDICTIVE GENETICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 342. BRICS PREDICTIVE GENETICS MARKET SIZE, BY SAMPLE SOURCE, 2018-2032 (USD MILLION)
  • TABLE 343. BRICS PREDICTIVE GENETICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 344. BRICS PREDICTIVE GENETICS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 345. BRICS PREDICTIVE GENETICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 346. BRICS PREDICTIVE GENETICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 347. EUROPEAN UNION PREDICTIVE GENETICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 348. EUROPEAN UNION PREDICTIVE GENETICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 349. EUROPEAN UNION PREDICTIVE GENETICS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 350. EUROPEAN UNION PREDICTIVE GENETICS MARKET SIZE, BY SEQUENCING SERVICE, 2018-2032 (USD MILLION)
  • TABLE 351. EUROPEAN UNION PREDICTIVE GENETICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 352. EUROPEAN UNION PREDICTIVE GENETICS MARKET SIZE, BY CANCER SCREENING, 2018-2032 (USD MILLION)
  • TABLE 353. EUROPEAN UNION PREDICTIVE GENETICS MARKET SIZE, BY CARRIER SCREENING, 2018-2032 (USD MILLION)
  • TABLE 354. EUROPEAN UNION PREDICTIVE GENETICS MARKET SIZE, BY PHARMACOGENOMICS, 2018-2032 (USD MILLION)
  • TABLE 355. EUROPEAN UNION PREDICTIVE GENETICS MARKET SIZE, BY PRENATAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 356. EUROPEAN UNION PREDICTIVE GENETICS MARKET SIZE, BY RISK ASSESSMENT, 2018-2032 (USD MILLION)
  • TABLE 357. EUROPEAN UNION PREDICTIVE GENETICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 358. EUROPEAN UNION PREDICTIVE GENETICS MARKET SIZE, BY MICROARRAY, 2018-2032 (USD MILLION)
  • TABLE 359. EUROPEAN UNION PREDICTIVE GENETICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 360. EUROPEAN UNION PREDICTIVE GENETICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 361. EUROPEAN UNION PREDICTIVE GENETICS MARKET SIZE, BY SAMPLE SOURCE, 2018-2032 (USD MILLION)
  • TABLE 362. EUROPEAN UNION PREDICTIVE GENETICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 363. EUROPEAN UNION PREDICTIVE GENETICS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 364. EUROPEAN UNION PREDICTIVE GENETICS MARKET SIZE, BY ONCOLO